Compare UG & CVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UG | CVM |
|---|---|---|
| Founded | 1942 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.5M | 30.1M |
| IPO Year | 1995 | 1996 |
| Metric | UG | CVM |
|---|---|---|
| Price | $7.08 | $1.67 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 6.9K | ★ 108.8K |
| Earning Date | 05-11-2026 | 05-13-2026 |
| Dividend Yield | ★ 7.10% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.20 | N/A |
| Revenue | ★ $10,545,468.00 | $264,033.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $36.25 | ★ N/A |
| Revenue Growth | N/A | ★ 65.45 |
| 52 Week Low | $5.58 | $0.89 |
| 52 Week High | $8.45 | $10.83 |
| Indicator | UG | CVM |
|---|---|---|
| Relative Strength Index (RSI) | 50.51 | 60.05 |
| Support Level | $6.90 | $0.95 |
| Resistance Level | $7.48 | $1.76 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 35.35 | 75.41 |
United-Guardian Inc manufactures, markets and develops specialty cosmetic, personal care and sexual wellness ingredients, and a line of healthcare products including pharmaceuticals and medical lubricants. Its pharmaceutical products are distributed through national drug wholesalers to pharmacies, physicians, and hospitals. It operates in one business segment and its current product lines are separated into four distinct product categories that are cosmetic ingredients, pharmaceuticals, medical lubricants and sexual wellness. The company's majority of revenue is derived from the sales of Pharmaceuticals in the United States.
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.